Hims & Hers Reports 59% Revenue Growth, Faces Regulatory Challenges

Hims & Hers Health, Inc. has reported remarkable growth in its fiscal year 2025 earnings, showcasing a 59% increase in revenue to $2.35 billion and a 13% rise in subscribers. Despite these strong results, the company is grappling with near-term margin pressures and potential regulatory scrutiny from the U.S. Securities and Exchange Commission (SEC).

In its fourth quarter of FY25, Hims & Hers posted a GAAP earnings per share of $0.08, exceeding analysts’ expectations by approximately $0.03. Revenue for the quarter reached $617.82 million, aligning closely with forecasts. Looking ahead, management has projected FY26 revenue between $2.7 billion and $2.9 billion, with an expected Adjusted EBITDA of $300 million to $375 million. This guidance indicates a strategic focus on international expansion and the development of new specialties, rather than solely prioritizing margin optimization.

Regulatory Scrutiny and Market Response

The SEC has initiated an investigation into Hims & Hers concerning its disclosures about compounded semaglutide, which has introduced regulatory uncertainty. This scrutiny contributed to a 9% decline in the company’s stock price following the earnings announcement. Investors are closely watching how this potential regulatory issue will impact the company’s operations and growth trajectory.

Despite the challenges posed by regulatory scrutiny, Hims & Hers continues to demonstrate resilience. The company’s stock currently trades at 1.5–1.8 times its sales and 26 times its forward earnings, reflecting a diversified subscription platform that remains attractive to investors.

Future Outlook and Investment Strategy

As Hims & Hers navigates these challenges, the focus on expanding internationally and enhancing its product offerings may position the company for sustained growth. Analysts suggest that while the current regulatory environment poses risks, the overall fundamentals of the business remain strong.

In light of these developments, I maintain a hold rating on Hims & Hers at current stock levels. The company’s ability to balance growth initiatives with regulatory compliance will be crucial in the coming quarters as it seeks to build on its significant revenue growth and subscriber expansion.

The future of Hims & Hers Health will depend not only on its financial performance but also on how effectively it addresses regulatory concerns and sustains investor confidence.